What’s New in Ocular Drug Delivery: Advances in Suprachoroidal Injection since 2023
Pharmaceuticals · 30.07.2024 · 17 (8) · 1007
DOI: 10.3390/ph17081007 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 30.07.2024. Verfasst von Kevin Y Wu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Division of Ophthalmology, University of Sherbrooke, Sherbrooke, QC J1G 2E8, Canada. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 173 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Despite significant advancements in ocular drug delivery, challenges persist in treating posterior segment diseases like macular edema (ME) and age-related macular degeneration (AMD). Suprachoroidal (SC) injections are a promising new method for targeted drug delivery to the posterior segment of the eye, providing direct access to the choroid and retina while minimizing systemic exposure and side effects. This review examines the anatomical and physiological foundations of the SC space; evaluates delivery devices such as microcatheters, hypodermic needles, and microneedles; and discusses pharmacokinetic principles. Additionally, advancements in gene delivery through SC injections are explored, emphasizing their potential to transform ocular disease management. This review also highlights clinical applications in treating macular edema, diabetic macular edema, age-related macular degeneration, choroidal melanoma, and glaucoma. Overall, SC injections are emerging as a promising novel route for administering ophthalmic treatments, with high bioavailability, reduced systemic exposure, and favorable safety profiles. Key therapeutic agents such as triamcinolone acetonide, dexamethasone, AAV-based gene therapy, and axitinib have shown promise. The field of suprachoroidal injection is progressing rapidly, and this review article, while attempting to encapsulate most of the published preclinical and clinical studies, mainly focuses on those that are published within 2023 and 2024.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, Division of Ophthalmology, University of Sherbrooke, Sherbrooke, QC J1G 2E8, Canada.
- Faculty of Medicine, Queen's University, Kingston, ON K7L 3N6, Canada.
- Faculty of Dental Medicine and Oral Health Sciences, McGill University, Montreal, QC H3A 1G1, Canada.
ORCID-Profile: Kevin Y Wu, Simon D Tran
Zitieren
APA
Wu, K. Y., Gao, A., Giunta, M., & Tran, S. D. (2024). What’s New in Ocular Drug Delivery: Advances in Suprachoroidal Injection since 2023. Pharmaceuticals, 17(8), 1007. https://doi.org/10.3390/ph17081007
Vancouver
Wu KY, Gao A, Giunta M, Tran SD. What’s New in Ocular Drug Delivery: Advances in Suprachoroidal Injection since 2023. Pharmaceuticals. 2024;17(8):1007. doi:10.3390/ph17081007
BibTeX
@article{Wu2024,
author = {Wu, Kevin Y and Gao, Angel and Giunta, Michel and Tran, Simon D},
title = {What’s New in Ocular Drug Delivery: Advances in Suprachoroidal Injection since 2023},
journal = {Pharmaceuticals},
year = {2024},
volume = {17},
number = {8},
pages = {1007},
doi = {10.3390/ph17081007}
}
EUVIMED